Company: Resverlogix Corp.
Symbol: TSX: RVX
Length: 00:20:29
Presenter: Donald J. McCaffrey, President and CEO
Occasion: Richmond Club Lunch, Toronto
Resverlogix Corp. (TSX: RVX) is a clinical stage cardiovascular company with an epigenetic platform technology that modulates protein production. Resverlogix is developing RVX-208, a first-in-class small molecule for the treatment of atherosclerosis. RVX-208 is the first BET bromodomain inhibitor in clinical trials.

More About Resverlogix
New compounds arising from Resverlogix’s epigenetic drug development platform function by inhibiting BET bromodomains and have the potential to impact multiple diseases including neurodegenerative diseases and diabetes mellitus.
Our Business Model is to seek strategic opportunities through early alliance partnerships that are best suited to bring our technology platforms to successful commercialization. We are committed to good corporate governance and protection of shareholder value.
In 2000, Donald McCaffrey was President of BioFuture, a national conference that brought academia and industry together featuring prominent researchers from universities across North America and representatives from the biotechnology industry. Dr. Norman Wong, a clinician who had been researching atherosclerosis and ApoA-I, met Don while presenting at BioFuture 2000. During the conference they discussed the paradigm shift in the treatment of atherosclerosis from the reduction of LDL cholesterol to raising HDL cholesterol. With the common goal to develop better therapies for the treatment of cardiovascular diseases, Don and Norm founded Resverlogix. Their combined talent, along with the addition of instrumental new employees in science and business, formed the foundation that has made Resverlogix the success it is today.
Head Office:
Resverlogix Corp.
300, 4820 Richard Road SW
Calgary, AB, CANADA, T3E 6L1
Telephone: 1 631-756-9116

Leave a Comment

Your email address will not be published. Required fields are marked *

Get Access to The Richmond Clubs Latest Stock Picks For FREE!


Don’t miss your chance to get in on the top stocks we think are the best buys now inside our exclusive Richmond Club Stock Advisor Letter.

Led by Chartered Investment Manager, Greg Beckett, the average stock pick inside The Richmond Club is up 1,301% vs. just 153% for the S&P.

This is your opportunity to become part of an exclusive membership led by the Richmond Club that has seen an average of 16.45 % gains over the past 15 years!

If you want to take advantage of this buying opportunity, simply enter your email address below to access our secure sign-up page.

Join The Richmond Advisor Free For 2-Months

By submitting your email address, you consent to us keeping you informed about updates to our website and about other products and services that we think might interest you. You can unsubscribe at any time. Please read our Privacy Policy